News and Announcements

AstraZeneca's Covid drug meets trial endpoints

By Abigail Townsend

Date: Thursday 16 May 2024

(Sharecast News) - AstraZeneca said on Thursday that its investigative drug sipavibart had shown positive results in preventing Covid-19 in vulnerable patients.
The FTSE 100 drugs firm said the phase III pre-exposure prophylaxis trial had met both its primary endpoints, of showing a relative risk reduction of Covid caused by different...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page